摘要
目的:通过对比研究153Sm-EDTMP和唑来膦酸治疗前列腺癌骨转移,以了解153Sm-EDTMP治疗前列腺癌骨转移的疗效。方法:确诊前列腺癌骨转移患者55例,分两组,一组31例用153Sm-EDTMP按37.0 MBq/kg体重静脉注射治疗,一组24例用唑来膦酸4 mg加入0.9%氯化钠注射液100 ml中缓慢静滴。治疗前及治疗后1～2个月行99mTc-MDP骨扫描检查。结果:153Sm-EDTMP组疼痛缓解有效率为83.9%,骨代谢改变有效率为64.5%。唑来膦酸组疼痛缓解有效率为58.3%,骨代谢改变有效率为33.3%。经χ2检验,两组疼痛缓解有效率比较χ2=4.448,P=0.035,骨代谢改变有效率比较χ2=5.263,P=0.022,均有显著性差异。结论:153Sm-EDTMP是治疗前列腺癌骨转移较理想的药物。
Objective： To investigate the efficacy of 153 Sm-EDTMP in the treatment of bone metastasis of prostate cancer （PCa） by comparison with zoledronic acid. Methods ： We assigned 55 PCa patients with bone metastasis to receive 153 Sm-EDTMP （ n = 31 ） and zoledronic acid （n = 24）, the former injected intravenously at the dose of 37.0 MBq/kg body weight, and the latter administered by slow intravenous drip at 4 mg in 100 ml of O. 9% sodium chloride. We performed 99 mTc-MDP bone scan before and 1 -2 months af- ter the treatment. Results： The rate of pain relief was 83.9% in the 153 Sm-EDTMP group and 58.3% in the zoledronic acid group （p = 0.035）, and that of bone metabolism change was 64.5% in the former and 33, 3% in the latter （P = 0.022）. Conclusion 153 Sm-EDTMp is an ideal agent for the treatment of prostate cancer with bone metastasis.
出处
《中华男科学杂志》
CAS
CSCD
2012年第11期982-985,共4页
National Journal of Andrology
